Cargando…

Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) amplification is a molecular driver for a subset of colorectal cancers (CRCs) and one of the major causes of anti-epidermal growth factor receptor (EGFR) treatment failure. Compared to dual anti-HER2 treatments, which have been shown to be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Ji-Lin, Liu, Jian-Hua, Wang, Qing, Cong, Yu-Wei, Chen, Yao-Xu, Huang, Ke-Fei, Huang, Meng-Li, Huang, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509996/ https://www.ncbi.nlm.nih.gov/pubmed/33005299 http://dx.doi.org/10.4251/wjgo.v12.i9.1065

Ejemplares similares

Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
por: Yu, Tosol, et al.
Publicado: (2016)

Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2‐positive breast cancer: a meta‐analysis of randomized controlled trials
por: Xin, Yong, et al.
Publicado: (2016)

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models
por: Formisano, Luigi, et al.
Publicado: (2014)

Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review
por: Zhang, Xiao, et al.
Publicado: (2014)

A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine
por: Nakao, Takayuki, et al.
Publicado: (2019)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials
por: SUN, JINZHONG, et al.
Publicado: (2015)

Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report
por: NOGUCHI, EIICHIRO, et al.
Publicado: (2014)

Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma
por: Chen, Yu-Jen, et al.
Publicado: (2014)

Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes
por: Dai, ChunLing, et al.
Publicado: (2015)

Lapatinib Inhibits Breast Cancer Cell Proliferation by Influencing PKM2 Expression
por: Guan, Mingxiu, et al.
Publicado: (2018)

Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Shen, Le-Sang, et al.
Publicado: (2020)

Advanced hormone receptor-positive/human epidermal growth factor receptor 2-positive invasive ductal carcinoma with cecal metastasis: A case report
por: Yang, Si-Yuan, et al.
Publicado: (2023)

Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population
por: Ni, Shujuan, et al.
Publicado: (2022)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
por: Chia, Stephen K., et al.
Publicado: (2017)

miR‐221 confers lapatinib resistance by negatively regulating p27(kip1) in HER2‐positive breast cancer
por: Huynh, Thanh Kieu, et al.
Publicado: (2021)

FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
por: Chung, Wei-Pang, et al.
Publicado: (2022)

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
por: Price, Timothy, et al.
Publicado: (2020)

Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis
por: Tian, Wei-Jie, et al.
Publicado: (2016)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report
por: Yue, Li, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Mutations in Colorectal Cancer Patients
por: Oh, Bo-Young, et al.
Publicado: (2011)

Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer
por: Sobani, Zain A, et al.
Publicado: (2016)

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone
por: Xu, Binghe, et al.
Publicado: (2014)

MicroRNA-370 inhibits the growth and metastasis of lung cancer by down-regulating epidermal growth factor receptor expression
por: Liu, Xin, et al.
Publicado: (2017)

Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study
por: Hua, Yijia, et al.
Publicado: (2022)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Proteomics identifies EGF‐like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor‐positive glioma
por: Wang, Fei‐yi‐fan, et al.
Publicado: (2020)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo
por: Mu, Yi, et al.
Publicado: (2018)

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
por: Toi, M, et al.
Publicado: (2009)

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer
por: Ye, Qing, et al.
Publicado: (2017)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer
por: Meng, Xiangjiao, et al.
Publicado: (2015)

Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer
por: De Pasquale, Maria Debora, et al.
Publicado: (2020)

Epidermal growth factor receptor-targeted immune magnetic liposomes capture circulating colorectal tumor cells efficiently
por: Kuai, Jing-Hua, et al.
Publicado: (2018)

Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer.
por: Kaklamanis, L., et al.
Publicado: (1992)

Lapatinib induces autophagic cell death and differentiation in acute myeloblastic leukemia
por: Chen, Yu-Jen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ldmhm6pijcs8if2gk2c8lgoh8m